文献速递妇科

三级评分系统评估子宫内膜癌淋巴血管间隙浸润的预后价值:系统综述与Meta分析

Prognostic value of three-tiered scoring system for lymph-vascular space invasion in endometrial cancer: A systematic review and meta-analysis.
PubMed 文献 · Gynecol Oncol · 2024-02-09

该系统综述与Meta分析共纳入9项研究、4456例子宫内膜癌患者,按三级评分系统评估淋巴血管间隙浸润(LVSI)状态与预后的关系。结果显示,与无LVSI组相比,局灶性和广泛性LVSI组的总体生存、无病生存更差,复发及淋巴结转移风险更高;广泛性LVSI组预后较局灶性LVSI组更差。作者认为三级LVSI评分系统可能有效预测子宫内膜癌预后并指导临床决策。

要点

  • 4456例子宫内膜癌患者中,无LVSI占72%,局灶性LVSI占16%,广泛性LVSI占13%。
  • 与无LVSI组相比,局灶性和广泛性LVSI组总体生存更差(局灶性HR 1.33,广泛性HR 2.51)。
  • 广泛性LVSI组较局灶性LVSI组更易发生盆腔复发(HR 1.82)和远处复发(HR 2.21)。

核心结论

  • 伴有局灶性和广泛性LVSI的子宫内膜癌患者较无LVSI患者生存更差、复发更多、淋巴结转移发生率更高。
  • 广泛性LVSI组预后较局灶性LVSI组更差。
  • 三级LVSI评分系统可能有效预测子宫内膜癌预后并指导临床决策。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、Embase、Cochrane对照试验中心注册库(CENTRAL)、国际临床试验注册平台(ICTRP)和ClinicalTrials.gov,检索时间从建库至2023年9月1日。
  • 共纳入9项研究、4456例子宫内膜癌患者,使用STATA 16.0进行分析。
  • 研究方案注册号:CRD 42023451793。

主要发现

  • 与无LVSI组相比,局灶性LVSI组总体生存HR 1.33(95%CI 1.02-1.74),广泛性LVSI组总体生存HR 2.51(95%CI 1.61-3.90)。
  • 与无LVSI组相比,广泛性LVSI组无病生存HR 2.86(95%CI 1.21-6.77)。
  • 与无LVSI组相比,局灶性LVSI组盆腔复发HR 2.05(95%CI 1.03-4.07),广泛性LVSI组盆腔复发HR 6.06(95%CI 3.31-11.08);局灶性LVSI组远处复发HR 2.04(95%CI 1.42-2.92),广泛性LVSI组远处复发HR 3.36(95%CI 2.35-4.793)。
  • 与无LVSI组相比,局灶性LVSI组淋巴结受累OR 3.52(95%CI 1.33-9.34),广泛性LVSI组淋巴结受累OR 5.42(95%CI 2.78-10.58);广泛性LVSI组较局灶性LVSI组更易发生盆腔复发(HR 1.82,95%CI 1.05-3.15)和远处复发(HR 2.21,95%CI 1.48-3.28)。

临床怎么用

  • 作者认为三级LVSI评分系统可能有效预测子宫内膜癌预后并指导临床决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the impact of lymph-vascular space invasion (LVSI) status on the prognosis of endometrial cancer (EC) according to a three-tiered scoring system for LVSI. METHODS: PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), International Clinical Trials Registry Platform (ICTRP), and Clinical Trials.gov were searched from inception to September 1st, 2023. The analysis was conducted using STATA 16.0. RESULTS: A total of 9 studies with 4456 EC patients were included in the analysis. No LVSI was found in 72% of EC patients (95% CI 0.65-0.79), while focal and substantial LVSI were present in 16% (95% CI 0.11-0.21) and 13% (95% CI 0.08-018) of patients, respectively. Compared to the no LVSI group, the focal and substantial LVSI groups had poorer overall survival (for focal LVSI: HR 1.33, 95% CI 1.02-1.74; for substantial LVSI: HR 2.51, 95% CI 1.61-3.90), poorer disease-free survival (for substantial LVSI: HR 2.86, 95% CI 1.21-6.77), and an increased risk of recurrence, including pelvic recurrence (for focal LVSI: HR 2.05, 95% CI 1.03-4.07; for substantial LVSI: HR 6.06, 95% CI 3.31-11.08), distant recurrence (for focal LVSI: HR 2.04, 95% CI 1.42-2.92; for substantial LVSI: HR 3.36, 95% CI 2.35-4.793), and lymph node involvement (for focal LVSI: OR 3.52, 95% CI 1.339.34; for substantial LVSI: OR 5.42, 95% CI 2.78-10.58). Substantial LVSI was more prone to pelvic recurrence (HR 1.82, 95% CI 1.05-3.15) and distant recurrence (HR 2.21, 95% CI 1.48-3.28) than focal LVSI. CONCLUSIONS: EC patients with focal and substantial LVSI had poorer survival, recurrence, and a higher incidence of lymph node metastasis than patients without LVSI. The substantial LVSI group was associated with even worse prognosis than the focal LVSI group. The three-tiered LVSI scoring system might effectively predict the prognosis of EC and guide clinical decision-making. PROTOCOL REGISTRATION: CRD 42023451793.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Han L, Chen Y, Zheng A, et al. Prognostic value of three-tiered scoring system for lymph-vascular space invasion in endometrial cancer: A systematic review and meta-analysis. Gynecol Oncol. 2024. PMID: 38335803. doi:10.1016/j.ygyno.2024.01.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。